FierceBiotech 4 mars 2026 Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset
FierceBiotech 3 mars 2026 New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program
FierceBiotech 3 mars 2026 Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
FierceBiotech 3 mars 2026 FDA details rationale for rejecting rare disease gene therapy from Regenxbio
FierceBiotech 3 mars 2026 MindMaze seeks 'strategic alternatives,' eyes US expansion as 2 board members exit
FierceBiotech 3 mars 2026 Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug
FierceBiotech 3 mars 2026 AI musculoskeletal imaging medtechs Medimaps and Radiobotics pen merger deal
FierceBiotech 3 mars 2026 GLP-1s support heart attack recovery in rodents by relaxing tight blood vessels
FierceBiotech 3 mars 2026 HHS bans Claude AI tool as Trump seeks full government blacklisting of Anthropic
FierceBiotech 2 mars 2026 Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout
FierceBiotech 2 mars 2026 TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio
FierceBiotech 2 mars 2026 Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline
FierceBiotech 2 mars 2026 BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline
FierceBiotech 2 mars 2026 United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition
FierceBiotech 2 mars 2026 UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy
FierceBiotech 2 mars 2026 Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking sock